Clinical Trial Update: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of DKN-01 in combination with tislelizumab, with or without chemotherapy, in gastric and gastroesophageal cancers was terminated and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• DKN-01 (dkn-01)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Leap Therapeutics, Inc. | Conditions: Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-10-09